Evidence map›Paper›PMID 36547187›Full record

ReviewCurrent oncology (Toronto, Ont.)2022

Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment.

Cornelia Speth, Ruben Bellotti, Georg Schäfer, Günter Rambach, Bernhard Texler, Gudrun C Thurner, Dietmar Öfner, Cornelia Lass-Flörl, Manuel Maglione

Open access · goldAbstract readReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Cornelia SpethInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Ruben BellottiDepartment of Visceral, Transplant, and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-9451-0794
Georg SchäferInstitute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Günter RambachInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-7574-7868
Bernhard TexlerDepartment of Visceral, Transplant, and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0001-5563-5618
Gudrun C ThurnerInstitute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0003-1592-7856
Dietmar ÖfnerDepartment of Visceral, Transplant, and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0001-8909-8566
Cornelia Lass-FlörlInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-2946-7785
Manuel MaglioneDepartment of Visceral, Transplant, and Thoracic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0003-1479-6129
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is still hampered by a dismal prognosis. A better understanding of the tumor microenvironment within the pancreas and of the factors affecting its composition is of utmost importance for developing new diagnostic and treatment tools. In this context, the complement system plays a prominent role. Not only has it been shown to shape a T cell-mediated immune response, but it also directly affects proliferation and apoptosis of the tumor cells, influencing angiogenesis, metastatic spread and therapeutic resistance. This makes complement proteins appealing not only as early biomarkers of PDAC development, but also as therapeutic targets. Fungal dysbiosis is currently the new kid on the block in tumorigenesis with cancer-associated mycobiomes extracted from several cancer types. For PDAC, colonization with the yeast Malassezia seems to promote cancer progression, already in precursor lesions. One responsible mechanism appears to be complement activation via the lectin pathway. In the present article, we review the role of the complement system in tumorigenesis, presenting observations that propose it as the missing link between fungal dysbiosis and PDAC development. We also present the results of a small pilot study supporting the crucial interplay between the complement system and Malassezia colonization in PDAC pathogenesis.

Indexed as

CarcinogenesisCarcinoma, Pancreatic DuctalDysbiosisMalasseziaPancreatic NeoplasmsComplement System ProteinsHumansPilot ProjectsPrognosisTumor MicroenvironmentComplement System Proteinscomplementfungal dysbiosisMalasseziamycobiomapancreastumorigenesistumor marker

Identifiers

PMID36547187
PMCPMC9777542
OpenAlexW4311788907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.